Jazz Pharmaceuticals plc (JAZZ) Financial Statements (2024 and earlier)

Company Profile

Business Address FIFTH FLOOR, WATERLOO EXCHANGE
DUBLIN, 4
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,5068815911,058637310
Cash and cash equivalents1,5068815911,058637310
Receivables706651563396356264
Inventory, net of allowances, customer advances and progress billings5977141,073957953
Inventory5977141,073957953
Prepaid expense18592131623925
Other current assets3212672521527968
Other undisclosed current assets120  1,075440515
Total current assets:3,4352,6062,6112,8401,6301,234
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization 456  
Operating lease, right-of-use asset657387129139
Property, plant and equipment    128132200
Intangible assets, net (including goodwill)7,1717,4878,9803,1533,3613,659
Goodwill1,7531,6931,828958920928
Intangible assets, net (excluding goodwill)5,4185,7947,1522,1952,4412,731
Deferred income tax assets478376311255221
Other noncurrent assets675541264843
Other undisclosed noncurrent assets1722332635767
Total noncurrent assets:7,9588,2299,6873,6963,9093,969
TOTAL ASSETS:11,39310,83512,2996,5365,5395,203
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities897894776405326307
Taxes payable1025111
Accounts payable10391100274841
Accrued liabilities794803666353268265
Deferred revenue  0235
Debt60531312463333
Contract with customer, liability5
Other undisclosed current liabilities357    
Total current liabilities:1,537933809654364345
Noncurrent Liabilities
Long-term debt and lease obligation5,1085,6936,1061,9891,7251,563
Long-term debt, excluding current maturities5,1085,6936,0191,8491,5741,563
Liabilities, other than long-term debt1,0121,1231,418234338228
Deferred revenue   025
Contract with customer, liability10
Deferred income tax liabilities8489441,301130224
Other liabilities105107117101109219
Operating lease, liability597287140151
Other undisclosed noncurrent liabilities      309
Total noncurrent liabilities:6,1206,8167,5242,2222,0632,101
Total liabilities:7,6567,7508,3332,8762,4282,446
Equity
Equity, attributable to parent, including:3,7373,0863,9653,6603,1112,757
Common stock000000
Additional paid in capital3,7003,4773,5352,6342,2662,114
Accumulated other comprehensive loss(842)(1,126)(400)(134)(223)(198)
Retained earnings8797348301,1601,068841
Other undisclosed equity, attributable to parent111111
Total equity:3,7373,0863,9653,6603,1112,757
TOTAL LIABILITIES AND EQUITY:11,39310,83512,2996,5365,5395,203

Income Statement (P&L) ($ in millions)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues3,8343,6593,0942,3642,1621,891
Cost of revenue(374)(502)(440)(149)(238) 
Gross profit:3,4603,1572,6542,2151,9241,891
Operating expenses(2,882)(3,223)(2,484)(1,837)(1,392)(1,276)
Operating income (loss):579(66)170378532615
Nonoperating income (expense)
(Gain (Loss), Foreign Currency Transaction, before Tax)
9(19)(4)(3)(6)(7)
Interest and debt expense (0)(0)(0)(76)(59)(57)
Other undisclosed loss from continuing operations before equity method investments, income taxes(289)(288)(278)(24)(13)(22)
Income (loss) from continuing operations before equity method investments, income taxes:298(373)(113)275454529
Loss from equity method investments(3)(10)(1)(3)(4)(2)
Income (loss) from continuing operations before income taxes:295(383)(114)272450527
Income tax expense (benefit)120159(216)(34)73(80)
Income (loss) from continuing operations:415(224)(330)239523447
Income (loss) before gain (loss) on sale of properties:(330)239523447
Net income (loss) available to common stockholders, basic:415(224)(330)239523447
Interest on convertible debt25     
Net income (loss) available to common stockholders, diluted:440(224)(330)239523447

Comprehensive Income ($ in millions)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):415(224)(330)239523447
Other comprehensive income (loss)(1) (266)89(26)(57)
Comprehensive income (loss):414(224)(596)328498390
Other undisclosed comprehensive income (loss), net of tax, attributable to parent285(725)    
Comprehensive income (loss), net of tax, attributable to parent:698(949)(596)328498390

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: